Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic Patients With "Acute-on-chronic Liver Failure"

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2012 by Instituto Grifols, S.A.
Sponsor:
Collaborator:
Hospital Clinic of Barcelona
Information provided by:
Instituto Grifols, S.A.
ClinicalTrials.gov Identifier:
NCT01201720
First received: August 27, 2010
Last updated: November 7, 2012
Last verified: November 2012
  Purpose

The purpose of this study is to evaluate the effects on plasma exchange with 5% albumin on albumin functional capacity, cardiocirculatory, renal and cerebral function in cirrhotic patients with "acute-on-chronic liver failure".


Condition Intervention Phase
Liver Cirrhosis
Liver Failure
Procedure: Plasma exchange with albumin
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Instituto Grifols, S.A.:

Primary Outcome Measures:
  • Albumin functional capacity [ Time Frame: 10 days ] [ Designated as safety issue: No ]
    Albumin binding capacity

  • Albumin functional capacity [ Time Frame: 10 days ] [ Designated as safety issue: No ]
    Electron Paramagnetic Resonance Spectroscopy

  • Albumin functional capacity [ Time Frame: 10 days ] [ Designated as safety issue: No ]
    Ischemia-modified albumin

  • Circulatory disfunction [ Time Frame: 10 days ] [ Designated as safety issue: No ]
    Plasma renin activity

  • Circulatory disfunction [ Time Frame: 10 days ] [ Designated as safety issue: No ]
    Plasma concentration of noradrenaline

  • Circulatory disfunction [ Time Frame: 11 days ] [ Designated as safety issue: No ]
    Systemic hemodynamic study and portal venous pressure


Secondary Outcome Measures:
  • Plasma concentration of blood urea nitrogen [ Time Frame: 1 month ] [ Designated as safety issue: No ]
  • Hepatic encephalopathy graded with the West Haven Criteria [ Time Frame: 1 month ] [ Designated as safety issue: No ]
  • Hepatic function parameters [ Time Frame: 1 month ] [ Designated as safety issue: No ]
    Conventional hepatic function parameters: aspartate transaminase, alanine transaminase, gamma-glutamyl transferase, alkaline phosphatase, total, conjugated and not conjugated serum bilirubin, serum albumin, international normalized ratio (INR) and prothrombin index

  • Plasma concentration of serum creatinine [ Time Frame: 1 month ] [ Designated as safety issue: No ]
  • Plasma concentration of sodium [ Time Frame: 1 month ] [ Designated as safety issue: No ]
  • Plasma concentration of potassium [ Time Frame: 1 month ] [ Designated as safety issue: No ]
  • Plasma concentration of phosphorus [ Time Frame: 1 month ] [ Designated as safety issue: No ]
  • hepatic toxins [ Time Frame: 10 days ] [ Designated as safety issue: No ]
    Hepatic toxin concentration: biliary acids, aromatic amino acids, ammonium and lactatum.


Estimated Enrollment: 10
Study Start Date: March 2011
Arms Assigned Interventions
Experimental: Albumin Procedure: Plasma exchange with albumin
Realization of 6 plasma exchange with albumin in 11 days and administration of polyclonal gamma globulin.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age between 18 and 80 years old
  • Hepatic cirrhosis diagnosed by biopsy or clinical, analytic and ultra sound data.
  • acute on chronic liver failure: defined by an acute deterioration in hepatic function produced in 2-4 weeks with jaundice (total serum bilirubin ≥ 5 mg/dl ) and hepatic encephalopathy (≥ grade 2) and/or renal insufficiency (serum creatinine ≥ 2 mg/dl)

Exclusion Criteria:

  • Neoplasm disease including hepatocarcinoma which exceed Milan criteria (1 tumour > 5cm, up to 3 tumours <3 cm)
  • Active bacterial or fungal infection with hemodynamic instability which require the utilization of vasoactive drugs at moderate dose (>0,5 μg/Kg/min of noradrenaline)
  • Structural moderate to severe cardiopathy (Cardiac Index <2l/min/m2)
  • Chronic renal insufficiency in treatment with haemodialysis
  • Chronic moderate o severe pulmonary disease (maximum expiratory volume in a second <50%)
  • Active transplant
  • human immunodeficiency virus infection
  • Pregnancy or lactation
  • Acute respiratory distress syndrome (P02/Fi02< 200mm Hg) or acute lung injury (P02/Fi02< 300mm Hg)
  • Hemodynamic instability (>0,5 μg/Kg/min of noradrenaline)
  • Bleeding in the digestive tract in the previous 72h to the treatment
  • Severe coagulopathy: INR ≥ 3.0 (Quick ≤ 20%) and/or platelets < 30000//mm3
  • Extrahepatic cholestasis
  • Hepatobiliary surgery in the last 6 months (except laparoscopic Cholecystectomy)
  • Concentrations bilirubin ≥ 5mg/dl during the period above 4 weeks previous to inclusion
  • Concomitant participation in an other clinical trial
  • Drug addiction
  • Mental status which does not allow the patient to understand the trial, with the exception of hepatic encephalopathy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01201720

Contacts
Contact: Ana Cruceta +34932275400 ext 9838 acruceta@clinic.ub.es

Locations
Spain
Hospital Clínic of Barcelona Recruiting
Barcelona, Spain, 08028
Principal Investigator: Vicente Arroyo, MD         
Sponsors and Collaborators
Instituto Grifols, S.A.
Hospital Clinic of Barcelona
Investigators
Principal Investigator: Vicente Arroyo, MD Hospital Clínic of Barcelona
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT01201720     History of Changes
Other Study ID Numbers: IG0905
Study First Received: August 27, 2010
Last Updated: November 7, 2012
Health Authority: Spain: Agencia Española de Medicamentos y Productos Sanitarios

Keywords provided by Instituto Grifols, S.A.:
cirrhosis
cirrhotic patients with acute on chronic liver failure

Additional relevant MeSH terms:
Liver Cirrhosis
Liver Failure
Liver Diseases
Digestive System Diseases
Hepatic Insufficiency

ClinicalTrials.gov processed this record on September 29, 2014